Lifeward Enters High-Interest Secured Promissory Note Financing

Lifeward ( (LFWD) ) has shared an update.

On February 12, 2026, Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for an initial principal of $525,000, potentially rising by an additional $975,000 by mutual consent. The note, secured by a lien on the company’s cash, carries a 24% annual interest rate and matures on August 12, 2026, or earlier if shareholders fail to approve transactions under previously signed securities and share purchase agreements dated January 12, 2026.

The financing imposes covenants that restrict Lifeward’s ability to incur further debt, grant liens, undertake major corporate changes, or transact with affiliates, and it includes standard default triggers such as non-payment, covenant breaches, insolvency, or a material adverse effect. In an event of default, Oramed can accelerate repayment, raise the interest rate, terminate its commitments, and enforce remedies, while any collateral proceeds will be applied ratably to both the new and existing $3.0 million secured notes, tightening the company’s financial discipline and elevating lender protections.

The most recent analyst rating on (LFWD) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Lifeward stock, see the LFWD Stock Forecast page.

Spark’s Take on LFWD Stock

According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.

The score is held down primarily by very weak profitability and heavy cash burn despite solid revenue growth and low debt. Technicals are neutral with only modest improving momentum, and valuation is constrained by ongoing losses (negative P/E). Offsetting factors include operational improvements and guidance reaffirmation from the earnings call plus liquidity/strategic support from the Oramed-related financing and transactions, albeit with dilution and control-risk tradeoffs.

To see Spark’s full report on LFWD stock, click here.

More about Lifeward

Lifeward Ltd. operates in the healthcare and life sciences sector, focusing on medical and pharmaceutical-related transactions and collaborations. Its financing arrangements and agreements with Oramed Pharmaceuticals and related entities underscore a strategic reliance on structured debt and equity-linked deals to support its ongoing corporate and transactional activities.

Average Trading Volume: 495,059

Technical Sentiment Signal: Sell

Current Market Cap: $9.64M

For detailed information about LFWD stock, go to TipRanks’ Stock Analysis page.